Physician profile
Allison Patterson
NPI 1386003937
$4,488.81
in general payments reported to CMS, 2019-2025
31 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $848 · 2023: $697 · 2024: $1,410 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $839.64 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $599.10 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $579.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $299.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Boostrix |
| Lilly USA, LLC | $249.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $209.04 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $166.04 | 2021-2025 | |
| Astellas Pharma US INC | $138.22 | 2021-2023 | Myrbetriq, Veozah |
| Abiomed | $132.28 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $123.10 | 2021-2025 | Verquvo |
| Exact Sciences Corporation | $119.17 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $116.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.63 | 2021-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $107.91 | 2022-2024 | Gvoke Hypopen |
| Pfizer INC. | $95.99 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $80.95 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $75.96 | 2025 | Onyx Frontier |
| Amgen INC. | $64.01 | 2024-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $56.19 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $47.39 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $45.97 | 2025 | Auvelity |
| Lundbeck LLC | $43.32 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $31.48 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $28.73 | 2021-2023 | |
| Genentech USA, INC. | $24.64 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.16 | 2024 | Rexulti |
| Viatris Specialty LLC | $21.63 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $20.30 | 2024 | Trintellix |
| Currax Pharmaceuticals LLC | $14.71 | 2022 | |
| Tactile Systems Technology INC | $13.15 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.